Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 49 references it cites were found in a registry or an index; 15 of the 19 sources its claims cite were checked for support.

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

Open access

Abstract

BACKGROUND: Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expression of metagenomic functions in the microbial community. METHODS: In melanoma patients undergoing immunotherapy, gut microbiome was characterized in pre-treatment stool using 16S rRNA gene and shotgun metagenome sequencing (n = 27). Transcriptional expression of metagenomic pathways was confirmed with metatranscriptome sequencing in a subset of 17. We examined associations of taxa and metagenomic pathways with progression-free survival (PFS) using 500 × 10-fold cross-validated elastic-net penalized Cox regression. RESULTS: Higher microbial community richness was associated with longer PFS in 16S and shotgun data (p < 0.05). Clustering based on overall microbiome composition divided patients into three groups with differing PFS; the low-risk group had 99% lower risk of progression than the high-risk group at any time during follow-up (p = 0.002). Among the species selected in regression, abundance of Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta were related to shorter PFS, and Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA to longer PFS. Metagenomic functions related to PFS that had correlated metatranscriptomic expression included risk-associated pathways of L-rhamnose degradation, guanosine nucleotide biosynthesis, and B vitamin biosynthesis. CONCLUSIONS: This work adds to the growing evidence that gut microbiota are related to immunotherapy outcomes, and identifies, for the first time, transcriptionally expressed metagenomic pathways related to PFS. Further research is warranted on microbial therapeutic targets to improve immunotherapy outcomes.

Overview

CoChat Summary

TL;DR

In a pilot study of 27 melanoma patients receiving immunotherapy, pre-treatment gut microbiome richness and composition were associated with progression-free survival (PFS), and metatranscriptomics identified expressed microbial pathways related to PFS. The work adds evidence that gut microbiota are related to immunotherapy outcomes and identifies transcriptionally expressed metagenomic pathways associated with PFS.

Key findings

  • Higher microbial community richness was associated with longer PFS: 16S s-OTUs HR [95% CI] = 0.97 [0.95, 1.00], p = 0.02; shotgun subspecies HR [95% CI] = 0.89 [0.79, 0.99], p = 0.03.
  • Clustering by overall microbiome composition divided patients into three groups with differing PFS; the low-risk group had 99% lower risk of progression than the high-risk group at any time during follow-up (HR [95% CI] = 0.01 [0.001, 0.20], p = 0.002), while the intermediate-risk group had non-significantly lower risk (HR [95% CI] = 0.10 [0.005, 2.17], p = 0.14).
  • Species related to shorter PFS included Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta; species related to longer PFS included Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA.
  • Metagenomic functions with correlated metatranscriptomic expression included risk-associated pathways of l-rhamnose degradation, guanosine nucleotide biosynthesis, and B vitamin biosynthesis, and protective pathways of l-isoleucine and petroselinate biosynthesis.

Methods

  • Pre-treatment stool samples from 27 patients with metastatic melanoma scheduled to receive immunotherapy at NYU Langone Health from September 2016 to November 2017, with follow-up through September 2018; samples underwent 16S rRNA gene and shotgun metagenome sequencing, and a subset of 17 underwent shotgun metatranscriptome sequencing after 10 samples failed library preparation due to poor RNA quality.
  • The primary endpoint was PFS, defined as disease progression or death from any cause; associations of taxa and metagenomic pathways with PFS were assessed using 500 × 10-fold cross-validated elastic-net penalized Cox regression, adjusting for age, sex, BMI, stage, number of sites of metastases, and antibiotic use in the last 6 months.
  • α-diversity and β-diversity were tested with Cox proportional hazards models, MiRKAT-S, OMiSA, and clustering with log-rank tests; functional features were filtered by prevalence, abundance, and variance, and metatranscriptomic correlations were examined with Spearman’s correlation, focusing on features selected ≥ 25% of 500 times, FDR-adjusted q < 0.20, and correlated metatranscriptomic expression p < 0.05.

Limitations

  • The paper states that the study is limited by its small sample size, had insufficient sample size to analyze adjuvant and metastatic patient groups separately, and could not analyze patient groups separately by immunotherapy treatment regimen.
  • The paper states that metatranscriptome sequencing data were available for only a subset of 17 patients, limiting power to assess relationships of metatranscriptomic expression and relative expression with PFS.
  • Evident from the text: this is a single-center pilot study with no independent validation cohort, and the observational design cannot establish causality.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13073-019-0672-4

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Patient clusters based on overall microbiome composition in 16S and shotgun data are related to progression-free survival. Ward’s Hierarchical Agglomerative Clustering method was used on the Jensen-Shannon Divergence (JSD) from the 16S s-OTU data and shotgun subspecies data to cluster patients into groups. a The dendrograms from 16S and shotgun were compared, and patients were assigned to two concordant groups (orange and blue) or a discordant group (purple). b The Kaplan-Meier curves of the patient groupings had significantly different progression-free survival (log-rank p = 0.0057)
Fig. 1 Patient clusters based on overall microbiome composition in 16S and shotgun data are related to progression-free survival. Ward’s Hierarchical Agglomerative Clustering method was used on the Jensen-Shannon Divergence (JSD) from the 16S s-OTU data and shotgun subspecies data to cluster patients into groups. a The dendrograms from 16S and shotgun were compared, and patients were assigned to two concordant groups (orange and blue) or a discordant group (purple). b The Kaplan-Meier curves of the patient groupings had significantly different progression-free survival (log-rank p = 0.0057)CC BY · PubMed Central
Fig. 2 Genera and species related to progression-free survival. a, b For genera or species selected > 125 times in 500 × 10-fold cross-validated elastic-net penalized Cox regression and with FDR-adjusted q < 0.20 in either the 16S or shotgun data, we show number of times selected and the hazard ratio. Note: not all genera and species were detected in both the 16S and shotgun data. c, d Scatterplots of 16S vs. shotgun relative abundance of genera and species, for genera and species selected in the regression and detected in both the 16S and shotgun data. Spearman’s rho and p value are displayed on the plots
Fig. 2 Genera and species related to progression-free survival. a, b For genera or species selected > 125 times in 500 × 10-fold cross-validated elastic-net penalized Cox regression and with FDR-adjusted q < 0.20 in either the 16S or shotgun data, we show number of times selected and the hazard ratio. Note: not all genera and species were detected in both the 16S and shotgun data. c, d Scatterplots of 16S vs. shotgun relative abundance of genera and species, for genera and species selected in the regression and detected in both the 16S and shotgun data. Spearman’s rho and p value are displayed on the plotsCC BY · PubMed Central
Fig. 3 Heatmap of shotgun species and subspecies relative abundance. Relative abundance of a species and b subspecies in the shotgun data; only those selected > 125 times in 500 × 10-fold cross-validated elastic-net penalized Cox regression and with FDR-adjusted q < 0.20 in either the 16S or shotgun data are shown. Ward’s Hierarchical Agglomerative Clustering method was used, column (patient) distance was based on the shotgun JSD (from Fig. 1), and row (species) distance on the Manhattan distance. Species and subspecies are annotated with the direction of their hazard ratio with progression-free survival, and patients are annotated with their combined JSD cluster (from Fig. 1)
Fig. 3 Heatmap of shotgun species and subspecies relative abundance. Relative abundance of a species and b subspecies in the shotgun data; only those selected > 125 times in 500 × 10-fold cross-validated elastic-net penalized Cox regression and with FDR-adjusted q < 0.20 in either the 16S or shotgun data are shown. Ward’s Hierarchical Agglomerative Clustering method was used, column (patient) distance was based on the shotgun JSD (from Fig. 1), and row (species) distance on the Manhattan distance. Species and subspecies are annotated with the direction of their hazard ratio with progression-free survival, and patients are annotated with their combined JSD cluster (from Fig. 1)CC BY · PubMed Central
Fig. 4 Metagenomic functional pathways related to progression-free survival. For metagenomic pathways selected > 125 times in 500 × 10-fold cross-validated elastic-net penalized Cox regression, that also had FDR-adjusted q < 0.20 and correlated (p < 0.05) metatranscriptomic expression, we show a number of times selected and the hazard ratio (alongside parallel data from the metatranscriptomic analysis in n = 17) and b correlations between metagenomic and metratranscriptomic functional pathway relative abundance. Spearman’s rho and p value are displayed on the plots. c MetaCyc pathway layouts for the pathways in (a, b). Each arrow represents one MetaCyc reaction, color-coded by its hazard ratio in the metagenomic analysis. Arrows in black represent reactions not tested due to low carriage, abundance, or variance of the reaction
Fig. 4 Metagenomic functional pathways related to progression-free survival. For metagenomic pathways selected > 125 times in 500 × 10-fold cross-validated elastic-net penalized Cox regression, that also had FDR-adjusted q < 0.20 and correlated (p < 0.05) metatranscriptomic expression, we show a number of times selected and the hazard ratio (alongside parallel data from the metatranscriptomic analysis in n = 17) and b correlations between metagenomic and metratranscriptomic functional pathway relative abundance. Spearman’s rho and p value are displayed on the plots. c MetaCyc pathway layouts for the pathways in (a, b). Each arrow represents one MetaCyc reaction, color-coded by its hazard ratio in the metagenomic analysis. Arrows in black represent reactions not tested due to low carriage, abundance, or variance of the reactionCC BY · PubMed Central
Fig. 5 Contribution of shotgun metagenome taxa to shotgun metagenome and metatranscriptome functional pathways. a Spearman’s correlations are shown for shotgun species and subspecies vs. shotgun metagenome and metatranscriptome pathways. Only taxa selected in repeated cross-validated elastic-net penalized Cox regression are shown, and only pathways selected in regression and that had correlated metatranscriptomic expression are shown. Taxa and pathways relative abundance were used for correlation analysis. Taxa and pathways are annotated with the direction of their hazard ratio with progression-free survival in the metagenomic analysis. *p < 0.05; **p < 0.01. b Mean percent contribution of species to functional pathways in the metagenome and metatranscriptome data. Per-species pathway abundance values were normalized to 100% for each pathway within each patient individually, and means were taken across patients; here, we show the mean percent contribution for the top 5 contributing species to each pathway. c Hazard ratios for species-specific pathway abundances; all species-by-pathway combinations existing in the data (for our selected species and pathways) are shown
Fig. 5 Contribution of shotgun metagenome taxa to shotgun metagenome and metatranscriptome functional pathways. a Spearman’s correlations are shown for shotgun species and subspecies vs. shotgun metagenome and metatranscriptome pathways. Only taxa selected in repeated cross-validated elastic-net penalized Cox regression are shown, and only pathways selected in regression and that had correlated metatranscriptomic expression are shown. Taxa and pathways relative abundance were used for correlation analysis. Taxa and pathways are annotated with the direction of their hazard ratio with progression-free survival in the metagenomic analysis. *p < 0.05; **p < 0.01. b Mean percent contribution of species to functional pathways in the metagenome and metatranscriptome data. Per-species pathway abundance values were normalized to 100% for each pathway within each patient individually, and means were taken across patients; here, we show the mean percent contribution for the top 5 contributing species to each pathway. c Hazard ratios for species-specific pathway abundances; all species-by-pathway combinations existing in the data (for our selected species and pathways) are shownCC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 5 Not checked · 89 Own results and interpretations

70 more claims

Create a free account to see all 104 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 13
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients datasets. 2019. Sequence Read Archive. https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA541981 .

Cited by

See all 263

Metadata

Authors
Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J.
Affiliations
  • NYU Langone Health (US)
  • Thomas Jefferson University (US)
Corresponding author
Ahn, Jiyoung
Venue
Genome Medicine
Published
2019-10-09
Volume
11
Issue
1
Pages
61-61
ISSN
1756-994X (ISSN-L)
OpenAlex
W2979785336
Cited by
263
References
49
Citations by year
2026: 34 · 2025: 40 · 2024: 56 · 2023: 47 · 2022: 38 · 2021: 33 · 2020: 12 · 2019: 2
FWCI
7.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Genome Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The Medicine Forum (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Cancer Institute (P50CA225450, P30CA016087, R01CA164964)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords
melanoma, immunotherapy response, gut microbiota, gut metagenome, metatranscriptome, progression-free survival, Bacteroides, Faecalibacterium prausnitzii, B vitamin biosynthesis, microbial metabolic pathways
MeSH terms
Gastrointestinal Microbiome, Aged, Feces, Female, Humans, Immunotherapy, Male, Melanoma, RNA, Ribosomal, 16S, Metagenome, Transcriptome, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. https://app.cochat.ai/papers/10.1186/s13073-019-0672-4
The paper
Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J. (2019). Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Medicine. https://doi.org/10.1186/s13073-019-0672-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.